Board of Directors
Verlyx’s management team is fortunate to work with an entrepreneurial and proactive board of directors who contribute significantly in shaping the strategic direction of the company.
Yves Roy, PhD
Chairman of the Board
Yves Roy has 30 years of experience in the consulting field across the world, advising companies of all sizes and helping manage, acquire and divest of companies.
Yves Roy held leadership responsibilities with Mercer LLC. in Canada, Latin-America, Europe and the United-States where he served as executive vice-president. After retiring from Mercer, he worked with a US based private-equity firm and then joined SECOR Group as president and CEO. He is a director of Le Groupe LMT (Les Métaux Tremblay), of IOU Financial and Verlyx Pharma where he chairs the Board of directors. He is also a member of the boards of the Fondation Marie-Vincent and the Fondation du Musée des Beaux-Arts de Montréal where he chairs the audit committee.
Mr. Roy earned an undergraduate degree in actuarial sciences from Université Laval, and is a Fellow of the Society of Actuaries (Chicago) and of the Canadian Institute of Actuaries. He also holds a PhD. in management and applied economics from the Wharton School of Business of the University of Pennsylvania.
Christian Chagnon is President of the investment firm Socama Inc. Prior to that, he was Managing Partner and a co-founder of IUGO Ventures, a company created in 2000 specialized in investments in emerging companies in the technology sector. He was formerly Senior Vice-President – Strategic Planning and Technology at Groupe Vidéotron Ltée. Mr. Chagnon sits or has served on the Board of Directors of several private companies, as well as of the Sainte-Justine UHC Foundation, and the Lucie and André Chagnon Foundation.
Bernard Dorval formerly served as Group Head of Business Banking, Insurance & Global Development at TD Bank Financial Group as well as Deputy Chair of TD Canada Trust. Over his tenure, he was responsible for most of the businesses and support areas of TD and Canada Trust successively leading Insurance, Investments and Trusts, Personal Lending, all Retail Banking products, Business Banking, Corporate Strategy and Global Development. Prior to that, Mr. Dorval served in a variety of management and Executive roles at Laurentian Group, eventually leading to his last appointment as CEO of the Life Insurance sector In 1994.
With a history of internal and external corporate board experience, Mr. Dorval currently serves as a member of the Board and Audit Committee of Rona Inc., as well as guest director on the board of Positron Access Solutions. Until recently, he was Chair of the Board of TD Insurance (Canada) and Chair of the Retirement Investment Committee of TD Bank Financial Group. An actuary by background, Mr. Dorval graduated from Quebec City’s Laval University in 1973 and became a Fellow Actuary in 1979. Over the years, he was recognised as “Young businessman of the year” by Montreal’s Junior Chamber of Commerce, seven times as a “top 25” by Finance and Investment, and is the recipient of the “School’s Medal of Glory” from his alma mater, Laval University. Mr. Dorval has been the Chairman of the Audit Committee of Verlyx Pharma since 2013.
Pierre Falardeau, PhD
President and Chief Executive Officer
Pierre Falardeau joined Verlyx Pharma in January 2010, as President and Chief Executive Officer. Dr. Falardeau has broad experience in drug development acquired over several years in the field of oncology. He is the founder of Consultation Pharm-Asset Inc., a consultation services in decision-support committed to delivering evidence-based business guidance to support global success in the pharmaceutical and biopharmaceutical industry, including financing strategy, portfolio optimization and product development.
From 2002 to 2007, Dr. Falardeau was President and Chief Executive Officer of Ecopia Biosciences Inc., until the merger of Ecopia with Caprion Pharmaceutical to form Thallion Pharmaceuticals, of which Dr. Falardeau became the Chief Operating Officer until 2009. From 1998 to 2002, he held increasingly responsible positions at Æterna-Zentaris, first as Director, Scientific Affairs, then as Vice-President, Scientific Affairs, with a focus in oncology.
From 1987 to 1991, Dr. Falardeau did his post-doctoral training at the Howard Hughes Medical Institute at Duke University, in Durham, North Carolina. Dr. Falardeau obtained his PhD in pharmacology and physiology in 1987 at Laval University, in Quebec City.
David Griller, PhD
A co-founder of Oncozyme Pharma, which became Verlyx Pharma in 2015, Dr. Griller obtained his PhD in Chemistry in 1978 at University College London, UK. He worked for the National Research Council of Canada from 1975 to 1988 where he was the head of Organic Chemistry. He is the author or co-author of over 200 scientific publications and patents and has received a number of awards and medals for his research. He is a fellow of the Royal Society of Canada and of the Chemical Institute of Canada. Dr. Griller has also been extensively involved in management consulting. He worked for Deloitte Haskins and Sells in the UK and KPMG (Canada). He joined SECOR in 1991 and was a partner there until 2012. He is now managing partner of Genspark Consulting.
Dr. Griller worked with Dr. Terry Chow to lay the foundations of Oncozyme Pharma. Working in close collaboration, they advanced Oncozyme’s technology from lab bench to human clinical trials and staked out the company’s core intellectual property position. Dr. Griller remains a board member, chair of the audit committee and an advisor to Verlyx’s management on scientific and intellectual property issues.
Michel Lagueux is President and Chief Executive Officer, Fonds Bio-Innovation Inc. Mr. Lagueux has extensive experience in the field of life sciences. He sits on the Board of several companies in the industry and is past Senior Vice-President, Life Sciences at the Fonds de solidarité, FTQ. He is also a past Vice-President of Innovatech Grand Montréal and has been involved in venture capital, in high tech life sciences, since 2002. Previously, Mr. Lagueux has started two companies and has worked for Pharmacia (now Pfizer) for 12 years, holding management positions in marketing, sales and finance.
Louise Proulx, PhD
Dr. Proulx holds a Ph.D. in physiology from Université Laval and pursued post-doctoral studies at the Karolinska Institute in Stockholm. She has close to 30 years experience in research and development management. She has held, over the years, scientific positions of increasing responsibilities, notably as Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, Vice President, Therapeutic Product Development at BioChem Pharma Inc., Vice President, Business Development of Genome Quebec and Vice-Principal Research at McGill University. She then returned to the pharmaceutical industry where she has been Vice President, Product Development at ViroChem Pharma Inc. She then became Vice-President, and Site Head, at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals. She is now Chief Development Officer at Therillia. Dr.Proulx has been a member of several boards of directors over her career and she is currently a member of the board of directors of Diagnocure Inc., the Canada Foundation for Innovation, the Research Institute of the McGill University Health Center, Gestion Univalor and BioQuébec. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors.
Lorne Trottier, C.M., PhD
Engineer, entrepreneur and philanthropist, Lorne Trottier has poured his passion for science into research, technological development and education in Quebec. In 1976, he co-founded Matrox Electronic Systems Ltd., a company known for its innovative computer graphics products. Through his vision and keen business sense, Matrox has become a Quebec-based world-leading multinational company in the field of high tech. Mr. Trottier is also unfailing in the support of his alma mater, McGill University, in addition to supporting Polytechnique Montréal and the Montréal Science Centre.
Reginald Weiser, P.Eng.
Reginald Weiser, P.Eng., is the founder and CEO of Positron Inc. He is a fellow of the Canadian Academy of Engineering and was the recipient of the Quebec Entrepreneur of the Year award in 1999. Reginald Weiser has been a lead investor in several high technology companies in the Montréal area.